Enteroglucagon, bowel growth and GLP-2.

Mol Cell Endocrinol

Prince Henry's Institute of Medical Research and Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.

Published: September 1997

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0303-7207(97)00137-8DOI Listing

Publication Analysis

Top Keywords

enteroglucagon bowel
4
bowel growth
4
growth glp-2
4
enteroglucagon
1
growth
1
glp-2
1

Similar Publications

Plasma glucagon-like peptide-2 in cats with chronic enteropathies.

J Feline Med Surg

January 2025

Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.

Objectives: The objective of this study was to compare plasma glucagon-like peptide-2 (GLP-2) concentrations in cats with chronic enteropathies (CE) with those of healthy cats.

Methods: Nineteen client-owned cats with a histopathologic diagnosis of either idiopathic chronic enteropathy (CIE) or low-grade lymphoma and six healthy client-owned cats were enrolled in a prospective study between 2 December 2021 and 9 June 2023. Fasted and postprandial plasma GLP-2 concentrations were measured via ELISA in CE cats at the time gastrointestinal biopsies were obtained and before CE treatment.

View Article and Find Full Text PDF

Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis.

Pediatr Surg Int

January 2025

Department of General and Thoracic Surgery, The Hospital for Sick Children, University of Toronto, 1526-555 University Ave, Toronto, ON, M5G 1X8, Canada.

Purpose: Necrotizing enterocolitis (NEC) majorly affects premature infants, causing not only necrosis and inflammation but also feeding intolerance and gastrointestinal dysmotility, hinting at gut hormone secretion impairment. Particularly critical is the gestation period before 26 weeks where intestinal hormonal activity is partially developed, rendering preterm neonates highly susceptible to NEC. Emerging evidence suggests a role of gut hormones, especially glucagon-like peptides (GLP) in ileum development.

View Article and Find Full Text PDF

Obesity and its associated intestinal inflammatory responses represent a significant global challenge. (IF) is a dietary intervention demonstrating various health benefits, including weight loss, enhanced metabolic health, and increased longevity. However, its effect on the intestinal inflammation induced by high-fat diet (HFD) is still not fully comprehended.

View Article and Find Full Text PDF

Cannabinoids are emerging as promising treatments for inflammatory diseases such as ulcerative colitis. Specifically, cannabinoid 2 (CB2) receptors, which are upregulated during inflammation, have been distinctively linked to anti-inflammatory and analgesic effects. HU308, a synthetic cannabinoid developed to activate CB2 receptors selectively, aims to minimize unwanted off-target side effects.

View Article and Find Full Text PDF

-Enriched Eicosatrienoic Acid Regulates Glucose Homeostasis by Promoting GLP-1 Secretion to Protect Intestinal Barrier Integrity.

J Agric Food Chem

January 2025

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China.

is a well-known probiotic with beneficial effects, such as anti-insulin resistance, anti-inflammatory, and improvement of the intestinal barrier. However, the underlying mechanisms remain unclear. Here, we found that gavage of improved the intestinal barrier and glucose homeostasis in HFD-fed mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!